Nifoxipam
Nifoxipam is a synthetic depressant of the nitrobenzodiazepine class and an active metabolite of flunitrazepam.1 It has potential applications in the short-term management of anxiety, insomnia, and acute seizures, but is currently available exclusively through research chemical vendors as a novel psychoactive substance. As with other benzodiazepines, it carries a risk of dependence1 and habit formation with repeated use.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of nifoxipam can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The general head space of nifoxipam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Nifoxipam acts as a positive allosteric modulator at the GABA-A receptor via the benzodiazepine binding site, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA).23 It belongs to the nitrobenzodiazepine subclass alongside nitrazepam, nimetazepam, flunitrazepam, and flurazepam. Its anticonvulsant properties may be due, in part or entirely, to binding at voltage-dependent sodium channels rather than the benzodiazepine site.
Pharmacokinetics
Nifoxipam (3-hydroxydesmethylflunitrazepam) is itself an active metabolite of flunitrazepam.3 No detailed pharmacokinetic parameters for nifoxipam have been reported in the available sources.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Benzodiazepines
Harm Potential
Addiction & Dependence
Psychological
HighDescribed as extremely psychologically addictive with significant abuse potential.3 Compulsive redosing is a noted effect, and regular use leads to habituation.2 Rebound anxiety following cessation can drive cycles of continued use and dependence.4
Physical
Extremely HighPhysical dependence develops with regular use over weeks, and withdrawal can be life-threatening.35 Abrupt discontinuation following extended use may result in hypertension, seizures, and potentially death.5 Gradual tapering over weeks is essential for safe discontinuation.4
Toxicity
Respiratory depression occurs at high doses and can be life-threatening in overdose or when combined with other CNS depressants; this effect is dose-dependent and uncommon at typical doses when used alone.6
Severe overdose may result in coma and permanent brain injury, primarily as a consequence of prolonged respiratory depression; this is mainly a concern in polydrug combinations or extreme dosing.6
Psychosis Risk
Paradoxical psychiatric reactions including aggression, violent behavior, irritability, loss of impulse control, and suicidal behavior occur rarely, with an incidence below 1% in the general population.7 Risk increases in recreational abusers, individuals with mental disorders, children, and those on high-dose regimens. Delusions may manifest during overdose.
Seizure Risk
Nifoxipam possesses anticonvulsant properties and does not induce seizures during typical use. Paradoxical seizure increase in epileptic individuals is rare. However, abrupt discontinuation after regular extended use carries significant seizure risk and may be fatal;54 gradual dose tapering is essential.
History & Culture
Nifoxipam is a nitrobenzodiazepine that was originally identified as a minor metabolite of flunitrazepam (marketed as Rohypnol).3 While it exists primarily as an analytical reference material in pharmacological research, the compound has since emerged on the…
Legality
By Country
References
Source Pages
Citations
- Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, & Schifano F. (2020). ‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports. Current Neuropharmacology, 18(9), 809–837. https://doi.org/10.2174/1570159x1866620011012133312
- Bhatt M, Bhatt S, & Bhatt S. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International, 13(4), 594-607. https://doi.org/10.3390/neurolint13040059123
- Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, & Athanaselis S. (2017). Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicology, 35(1), 1-10. https://doi.org/10.1007/s11419-016-0338-5123456789
- Brett J, & Murnion B. (2015). Management of benzodiazepine misuse and dependence. Australian Prescriber, 38(5), 152–155. https://pmc.ncbi.nlm.nih.gov/articles/PMC4657308/123
- (2009). A fatal case of benzodiazepine withdrawal. https://doi.org/10.1097/paf.0b013e3181875aa0123
- Bounds CG, & Nelson VL. (n.d.). Benzodiazepine Toxicity. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK482238/12345
- (2008). [Paradoxical aggressive reactions to benzodiazepine use: a review]. https://doi.org/10.1016/j.encep.2007.05.0051
- (June 2015). Designer benzodiazepines: A new challenge. World Psychiatry, 14(2), 248. https://doi.org/10.1002/wps.2023612
- (n.d.). Controlled Drugs and Substances Act, Schedule IV — Benzodiazepines. Government of Canada / Justice Laws Website. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html1
- (2019). § 4 NpSG. https://www.gesetze-im-internet.de/npsg/__4.html1
- (2016). Psychoactive Substances Act 2016. https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Nifoxipam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.